Aquestive Therapeutics details 2026 shareholder vote results
Aquestive Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 10, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Aquestive Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 10, 2026. Stockholders elected three Class II directors — Gregory B. Brown, M.D., John S. Cochran, and Abigail L. Jenkins — to serve three-year terms until the 2029 annual meeting.
Stockholders also approved, on a non-binding advisory basis, the Company’s executive compensation program, with 37,798,609 votes for, 3,192,381 against, and 1,604,754 abstentions, plus 37,465,582 broker non-votes. In addition, they ratified the appointment of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 78,804,323 votes for, 910,690 against, and 346,313 abstentions.
8-K Event Classification
2 items: 5.07, 9.01
2 items
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Votes for Brown: 41,373,033 votes
Votes abstaining on Brown: 1,222,711 votes
Votes for Cochran: 36,914,899 votes
+5 more
8 metrics
Votes for Brown
41,373,033 votes
Election of Gregory B. Brown, M.D. as Class II director
Votes abstaining on Brown
1,222,711 votes
Abstentions for Brown director election
Votes for Cochran
36,914,899 votes
Election of John S. Cochran as Class II director
Votes for Jenkins
39,094,166 votes
Election of Abigail L. Jenkins as Class II director
Say-on-pay votes for
37,798,609 votes
Advisory approval of executive compensation
Auditor ratification votes for
78,804,323 votes
Ratification of KPMG LLP as 2026 auditor
Auditor votes against
910,690 votes
Votes against KPMG LLP ratification
Auditor abstentions
346,313 votes
Abstentions on KPMG LLP ratification
Key Terms
non-binding advisory basis, independent registered public accounting firm, broker non-votes, Annual Meeting of Stockholders, +1 more
5 terms
non-binding advisory basis regulatory
"The proposal to approve, on a non-binding advisory basis, executive compensation was approved"
A non-binding advisory basis is guidance or a recommendation offered for informational purposes that does not create legal obligations or guarantees; recipients can accept, modify, or ignore it without contractual consequences. Investors should treat it like a weather forecast for planning—useful for forming expectations and assessing risk, but not a firm promise—so they should verify assumptions, seek confirming information, and avoid relying on it as the sole basis for investment decisions.
independent registered public accounting firm regulatory
"The appointment of KPMG LLP as the independent registered public accounting firm for the Company"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
broker non-votes financial
"Votes For 37,798,609 | Votes Against 3,192,381 | Votes Abstaining 1,604,754 | Broker Non-Votes 37,465,582"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
Annual Meeting of Stockholders regulatory
"Aquestive Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders on June 10, 2026"
Class II members of the Board of Directors regulatory
"The following director nominees were elected to serve as Class II members of the Board of Directors"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Aquestive Therapeutics (AQST) stockholders approve at the 2026 annual meeting?
Stockholders elected three Class II directors, approved executive compensation on a non-binding advisory basis, and ratified KPMG LLP as independent auditor for 2026. These actions confirm the existing board composition, pay practices, and audit relationship for the coming fiscal year.
Which directors were elected at Aquestive Therapeutics' 2026 annual meeting?
Stockholders elected Gregory B. Brown, M.D., John S. Cochran, and Abigail L. Jenkins as Class II directors. They will serve three-year terms until the 2029 annual meeting and until their successors are duly elected and qualified under the company’s governance structure.
Who is the independent auditor for Aquestive Therapeutics for fiscal year 2026?
KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026, receiving 78,804,323 votes for, 910,690 against, and 346,313 abstentions. This vote continues KPMG’s role in auditing the company’s financial statements.
Were there any broker non-votes at the Aquestive Therapeutics 2026 annual meeting?
Yes. There were 37,465,582 broker non-votes on the director elections and the advisory vote on executive compensation. Broker non-votes occur when brokers lack discretionary authority and the beneficial owner does not provide specific voting instructions on certain proposals.
What type of proposals were voted on at Aquestive Therapeutics’ 2026 meeting?
Stockholders voted on three proposal types: election of Class II directors, an advisory (non-binding) vote on executive compensation, and ratification of KPMG LLP as independent registered public accounting firm for 2026. All three proposals received sufficient support to be approved.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates